Amarantus Bioscience Holdings Inc (AMBS)

[Riskreturn168]

I have a question. I've never been able to understand why Psychogenics, (sp?) the company David Lowe used to work for and the company that licensed Eltoprazine to us...sat on such good data for over 5 years? Why would they do that? And then when they did license it out, why did they do it with a small company like us that can't pay them much cash for it?

I understand why it is nice for AMBS to have a drug deep into clinical trials, it makes our overall pipeline look more mature and that can influence the price target analysts give us. But I am trying to evaluate how good this drug really is and how much potential it truly has...if it sat untouched for over 5 years?

Don't get me wrong, I think it was a great move for us. I just need someone who understands this more to explain the 5 year waiting thing.

I'm surprised Gerald or David Lowe hasn't already addressed this aspect of the deal. To me it seems like an elephant in the room that before it can truly bump up our stock price...must be addressed, as well as how we'll fund the clinical trials. Eltoprazine carries with it a good deal of mystery, mystery that hasn't increased our value yet.